To test this hypothesis, we used three human tumor cell lines with varying degrees of HRR proficiency: SKOV-3 (BRCA2 WT [28]), MCF-7 (HRR deficient [29]), and CAPAN-1 (BRCA2 mutant [28]). This evidence concerns the gene BRCA2 and neoplasm.